Effects of treatment change in patients with neovascular
age-related macular degeneration; Results from the Czech
National Registry

J 2012

Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry

STUDNIČKA, Jan; Eva RENCOVÁ; Pavel ROZSÍVAL; Jaroslava DUŠOVÁ; Zora DUBSKÁ et al.

Základní údaje

Originální název

Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry

Autoři

STUDNIČKA, Jan; Eva RENCOVÁ; Pavel ROZSÍVAL; Jaroslava DUŠOVÁ; Zora DUBSKÁ; Oldřich CHRAPEK; Petr KOLÁŘ; Vít KANDRNAL; Šárka PITROVÁ a Jiří ŘEHÁK

Vydání

Biomedical Papers, Olomouc, 2012, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.990

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00062539

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

age-related macular degeneration; choroidal neovascular membrane; visual acuity; ranibizumab; pegaptanib; photodynamic therapy with verteporfin

Změněno: 11. 11. 2019 12:43, Mgr. Tereza Miškechová

Anotace

V originále

Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment. Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period. Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7% subjects treated with ranibizumab, 20.5% with pegaptanib and 22% with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +/- 3 letters and 43 +/- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +/- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +/- 2.1 months. Conclusion. BCVA loss was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium.

Návaznosti

MUNI/A/0841/2011, interní kód MU

Název: Zlepšení kvality života optimalizace funkce zrakového orgánu (Akronym: ZKZOFZA)

Investor: Masarykova univerzita, Zlepšení kvality života optimalizace funkce zrakového orgánu, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

STUDNIČKA, Jan; Eva RENCOVÁ; Pavel ROZSÍVAL; Jaroslava DUŠOVÁ; Zora DUBSKÁ; Oldřich CHRAPEK; Petr KOLÁŘ; Vít KANDRNAL; Šárka PITROVÁ a Jiří ŘEHÁK. Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. Biomedical Papers. Olomouc, 2012, roč. 156, č. 4, s. 359-364. ISSN 1213-8118. Dostupné z: https://doi.org/10.5507/bp.2012.100.

@article{1079967,
   author = {Studnička, Jan and Rencová, Eva and Rozsíval, Pavel and Dušová, Jaroslava and Dubská, Zora and Chrapek, Oldřich and Kolář, Petr and Kandrnal, Vít and Pitrová, Šárka and Řehák, Jiří},
   article_location = {Olomouc},
   article_number = {4},
   doi = {https://doi.org/10.5507/bp.2012.100},
   keywords = {age-related macular degeneration; choroidal neovascular membrane; visual acuity; ranibizumab; pegaptanib; photodynamic therapy with verteporfin},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers},
   title = {Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry},
   volume = {156},
   year = {2012}
}

TY  - JOUR
ID  - 1079967
AU  - Studnička, Jan - Rencová, Eva - Rozsíval, Pavel - Dušová, Jaroslava - Dubská, Zora - Chrapek, Oldřich - Kolář, Petr - Kandrnal, Vít - Pitrová, Šárka - Řehák, Jiří
PY  - 2012
TI  - Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry
JF  - Biomedical Papers
VL  - 156
IS  - 4
SP  - 359-364
EP  - 359-364
SN  - 12138118
KW  - age-related macular degeneration
KW  - choroidal neovascular membrane
KW  - visual acuity
KW  - ranibizumab
KW  - pegaptanib
KW  - photodynamic therapy with verteporfin
N2  - Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment. Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period. Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7% subjects treated with ranibizumab, 20.5% with pegaptanib and 22% with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +/- 3 letters and 43 +/- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +/- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +/- 2.1 months. Conclusion. BCVA loss was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium.
ER  -

STUDNIČKA, Jan; Eva RENCOVÁ; Pavel ROZSÍVAL; Jaroslava DUŠOVÁ; Zora DUBSKÁ; Oldřich CHRAPEK; Petr KOLÁŘ; Vít KANDRNAL; Šárka PITROVÁ a Jiří ŘEHÁK. Effects of treatment change in patients with neovascular age-related macular degeneration; Results from the Czech National Registry. \textit{Biomedical Papers}. Olomouc, 2012, roč.~156, č.~4, s.~359-364. ISSN~1213-8118. Dostupné z: https://doi.org/10.5507/bp.2012.100.

Přehled o publikaci